Followers | 55 |
Posts | 2608 |
Boards Moderated | 0 |
Alias Born | 02/04/2014 |
Tuesday, April 14, 2015 5:14:40 PM
Research supported by PharmaCyte Biotech, Inc., a biotechnology company developing treatments for cancer patients, determined that the company’s pancreatic cancer treatment is able to reduce malignant ascites’ fluid accumulation.
Ascites consist of a fluid build-up in the abdominal cavity that occurs in people with specific diseases, including liver, ovarian, uterine, gastrointestinal, pancreatic, and colon cancers (malignant ascites).
This treatment uses low doses of ifosfamide combined with the company’s Cell-in-a-Box®capsules, which contains live cells able that allow ifosfamide to kill cancer cells. In a preliminary investigation, 40 mice received human ovarian cancer cells (ES-2) that originate substantial quantities of malignant ascites fluid, and were allocated into 4 different groups: either receiving PharmaCyte Biotech’s pancreatic cancer treatment; receiving chemotherapy with cisplatin, an agent utilized as a treatment for ovarian cancer; receiving a combination of cisplatin and PharmaCyte Biotech’s pancreatic cancer treatment; or administered placebo as a control.
The team used the same ES-2 ovarian cancer model in a follow-up study where animals were allocated into 12 treatments groups to better delimit the factors that will be used in a prospective Phase 1 trial of human patients with accumulation of malignant ascites fluid as a consequence of abdominal cancer. This study will be conducted in the United States by TD2 and will led by Dr. Daniel D. Von Hoff in collaboration with PharmaCyte Biotech scientists.
“We are looking forward to the results of this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors such as in the case of ovarian cancer, who suffer from this very serious cancer-associated malady,” commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech in a recent news release.
The research team hopes their pancreatic treatment will be effective in reducing malignant ascites’ fluid accumulation in colon cancer patients, while reducing the number of fluid withdrawals that patients must tolerate. The goal is to help patients who suffer from ascites fluid accumulation, a major problem for patients suffering with abdominal cancer which causes pain and other serious complications. When ascites’ fluid levels get to a certain amount, they must be removed — a costly and uncomfortable procedure for patients.
http://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM